Anti-C1S (Sutimlimab), Humanized Antibody

Anti-C1S (Sutimlimab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a humanized IgG4 monoclonal antibody that targets human complement factor C1s. C1s is a serine protease that is part of the C1 complex which contains a pattern recognition receptor (C1q) and a C1s activating serine protease (C1r). Activation of C1 complex results in the formation of C3 convertase which cleaves to form C3a and C3b. Chronic activation of the complement system results in extravascular hemolysis which is responsible for the pathophysiology of anemia in cold agglutinin disease (CAD). Binding of the antibody to complement factor C1s prevents the activation of the complement system and subsequent hemolysis. However, the antibody does not affect immune surveillance functions of alternative and lectin complement pathways. Currently, the original drug received priority review status from the FDA to treat hemolysis in adult patients suffering from cold agglutinin disease (CAD).

Immunogen Sequence:Human C1S

Target Alternative Name:BIVV 009, BIVV-009, BIVV009, IPN 009, IPN-009, IPN009, TNT009, EDSPD2

Species Reactivities:/

Tag Line:The biosimilar is a humanized monoclonal antibody that targets complement C1s, a serine protease involved in the activation of the classical complement pathway (CP). This inactivation of the complement pathway prevents the mechanism of hemolysis in cold agglutinin disease (CAD)

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.